Saibeixin (Pazopanib) 200mg*30 | Qilu China Generic | GLT

Generic Information: Saibeixin (Pazopanib) 200mg — China-Mainland

Saibeixin (赛贝欣) is a Chinese generic of pazopanib manufactured by Qilu Pharmaceutical Co., Ltd., one of China's largest and most established pharmaceutical companies. Saibeixin was the first domestically approved pazopanib generic in China, receiving NMPA approval in 2023 (with the competing generic approved the same day), and is considered bioequivalent to the originator Votrient. This listing is the 200 mg tablet (0.2 g) in a 30-tablet pack.

Qilu is a leading Chinese oncology manufacturer with over a hundred products that have passed consistency evaluation. Saibeixin has been included in China's national medical insurance scheme for the renal cell carcinoma indication, and is priced meaningfully below the imported originator. For international buyers, it represents a first-mover Chinese generic with documented bioequivalence.

What Is Saibeixin Used For?

Saibeixin treats advanced renal cell carcinoma (RCC) in the first-line setting and after prior cytokine therapy, and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy. As a bioequivalent generic, it delivers the same anti-angiogenic therapy as the originator at a lower cost.

How Does Saibeixin Work?

Pazopanib, the active ingredient in Saibeixin, is a multi-targeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β) and c-Kit. By inhibiting these kinases, Saibeixin disrupts tumour angiogenesis, cutting off the blood supply that growing tumours require and slowing their progression.

Indications

• Advanced renal cell carcinoma (RCC), first-line and after prior cytokine therapy.
• Advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.

Dosage and Administration

The recommended dose is 800 mg once daily, taken as four 200 mg tablets on an empty stomach (at least 1 hour before or 2 hours after a meal), swallowed whole. A 30-tablet pack provides about one week of therapy. Dose adjustment is required for hepatic impairment, and liver function and blood pressure are monitored during treatment.

Side Effects

Common adverse reactions include diarrhoea, hypertension, hair colour changes, nausea, fatigue, decreased appetite and vomiting. Pazopanib carries a boxed warning for severe hepatotoxicity, so liver function is monitored before and during therapy. Hypothyroidism, haemorrhage and QT prolongation may occur, and patients should report yellowing, unusual bleeding or palpitations.

Storage

Store Saibeixin below 30°C in the original pack, away from moisture and out of the reach of children. Use before the expiry date printed on the pack.

Why Choose the GLT?

GLT sources Saibeixin through a documented China supply chain and verifies each batch against the manufacturer's details. As China's first approved pazopanib generic, Saibeixin is typically priced at a small fraction of the branded originator's US list price, making long-term anti-angiogenic therapy far more sustainable. We provide clear purchase documentation and direct contact for ongoing support.

How to Order Saibeixin from GLT

To order Saibeixin 200 mg (30 tablets), contact GLT on WhatsApp at +86 15234153837 or email [email protected]. Tell us your quantity, shipping destination and order type, and we confirm batch details and lead time before dispatch.

FAQ

Is Saibeixin the same as Votrient? Saibeixin contains the same active ingredient (pazopanib) and is bioequivalent to Votrient; it is China's first approved generic, by Qilu Pharmaceutical.

Is Saibeixin reimbursed in China? Yes, Saibeixin is included in China's national medical insurance scheme for the renal cell carcinoma indication.

What is the standard dose? 800 mg once daily (four 200 mg tablets), taken on an empty stomach.